ABL Diagnostics Valuation Multiples

ABL Diagnostics Overview

About ABL Diagnostics

ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

Founded

1929

HQ

Employees

N/A

Website

abldiagnostics.com

Financials (LTM)

Revenue: $11M

EBITDA: $2M

EV

$47M

Valuation Multiples

Start free trial

ABL Diagnostics Financials

ABL Diagnostics reported last 12-month revenue of $11M and EBITDA of $2M.

In the same LTM period, ABL Diagnostics generated $2M in EBITDA and $1M in net income.

ABL Diagnostics P&L

In the most recent fiscal year, ABL Diagnostics reported revenue of $8M and EBITDA of $1M.

ABL Diagnostics is profitable as of last fiscal year, with gross margin of 92%, EBITDA margin of 14%, and net margin of 14%.

ABL Diagnostics Stock Performance

ABL Diagnostics has current market cap of $46M, and enterprise value of $47M.

ABL Diagnostics' stock price is $2.85.

ABL Diagnostics has an EPS (earnings per share) of $0.07.

ABL Diagnostics Valuation Multiples

ABL Diagnostics trades at 4.3x EV/Revenue multiple, and 20.1x EV/EBITDA.

ABL Diagnostics Financial Valuation Multiples

As of July 28, 2026, ABL Diagnostics has market cap of $46M and EV of $47M.

ABL Diagnostics has a P/E ratio of 32.6x.

ABL Diagnostics Margins & Growth Rates

ABL Diagnostics grew revenue by 60% and EBITDA by 180% in the last fiscal year.

In the most recent fiscal year, ABL Diagnostics reported gross margin of 92%, EBITDA margin of 14%, and net margin of 14%.

ABL Diagnostics Operational KPIs

ABL Diagnostics' Rule of 40 is 90% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ABL Diagnostics' Rule of X is 189% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Acquisitions by ABL Diagnostics

ABL Diagnostics has acquired 1 company to date.

Last acquisition by ABL Diagnostics was on July 21st 2026. ABL Diagnostics acquired Texcell (certain assets) for $3M (EV/Revenue multiple available to Pro users).